on November 2, 2006
Published online before print November 2, 2006, doi: 10.1161/01.ATV.0000251503.35795.4f
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on August 30, 2006
Accepted on October 16, 2006
Biomarkers of Atherosclerotic Plaque Instability and Rupture
Wolfgang Koenig * and Natalie Khuseyinova
From the Department of Internal Medicine II-Cardiology, University of Ulm Medical Center, Germany.
* To whom correspondence should be addressed. E-mail: wolfgang.koenig{at}uniklinik-ulm.de.
Abstract--Basic research over the last two decades has identified a large number of molecules pertinent to the atherosclerotic process, which have clearly improved our understanding of the underlying pathology. It is now well established that inflammation represents a major feature which is present in the vessel wall throughout all stages of the disease until the final pathophysiologic steps, representing plaque destabilization and eventually plaque rupture. Several cells typical for the atherosclerotic plaque, like monocyte-derived macrophages and T-lymphocytes are able to produce and secrete such mediator molecules, like cytokines, chemokines, growth-factors, enzymes, and disintegrins, which lead to activation of endothelial cells, proliferation of smooth muscle cells, lesion progression, and finally to the weakening of a vulnerable plaque by matrix degradation of its fibrous cap. Today, many of these molecules involved can be measured systemically by sensitive assays, and elevated concentrations in the circulation have been shown to be associated with future cardiovascular events. Determination of several of these molecules carries important prognostic information, independent of traditional risk factors, and may turn out to be useful in improving risk stratification. However, for most of these biomarkers the clinical utility has not yet been established.
Key words: biomarkers • atherosclerosis • pathophysiology • risk prediction
This article has been cited by other articles:
 |
|
 |
|
  M. Markovic, S. Ignjatovic, N. Majkic-Singh, and M. Dajak Placental Growth Factor in Acute Coronary Syndrome Patients with Non ST-Elevation Lab Med, November 1, 2009; 40(11): 675 - 678. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.H. W. Tang Enhancing the Prognostic Value of Cardiac Imaging With Multimodal Risk Assessment J. Am. Coll. Cardiol. Img., September 1, 2009; 2(9): 1100 - 1102. [Full Text] [PDF]
|
|
|
|
 |
|
 S. U. Eisenhardt, J. Habersberger, A. Murphy, Y.-C. Chen, K. J. Woollard, N. Bassler, H. Qian, C. von zur Muhlen, C. E. Hagemeyer, I. Ahrens, et al. Dissociation of Pentameric to Monomeric C-Reactive Protein on Activated Platelets Localizes Inflammation to Atherosclerotic Plaques Circ. Res., July 17, 2009; 105(2): 128 - 137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Tian, R. Miyazaki, T. Ichiki, I. Imayama, K. Inanaga, H. Ohtsubo, K. Yano, K. Takeda, and K. Sunagawa Inhibition of Tumor Necrosis Factor-{alpha}-Induced Interleukin-6 Expression by Telmisartan Through Cross-Talk of Peroxisome Proliferator-Activated Receptor-{gamma} With Nuclear Factor {kappa}B and CCAAT/Enhancer-Binding Protein-{beta} Hypertension, May 1, 2009; 53(5): 798 - 804. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Wenwei Liu, Qizhu Tang, Hua Jiang, Xiangwu Ding, Yongsheng Liu, Rui Zhu, Yongqian Tang, Bin Li, and Min Wei Promoter Polymorphism of Interleukin-18 in Angiographically Proven Coronary Artery Disease Angiology, April 1, 2009; 60(2): 180 - 185. [Abstract] [PDF]
|
|
|
|
 |
|
 G. CELLA, F. VIANELLO, F. COZZI, H. MAROTTA, F. TONA, G. SAGGIORATO, O. IQBAL, and J. FAREED Effect of Bosentan on Plasma Markers of Endothelial Cell Activity in Patients with Secondary Pulmonary Hypertension Related to Connective Tissue Diseases J Rheumatol, April 1, 2009; 36(4): 760 - 767. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Koenig Is hsCRP Back on Board? Implications from the JUPITER Trial Clin. Chem., February 1, 2009; 55(2): 216 - 218. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Chandrasekar, W. H. Boylston, K. Venkatachalam, N. J. G. Webster, S. D. Prabhu, and A. J. Valente Adiponectin Blocks Interleukin-18-mediated Endothelial Cell Death via APPL1-dependent AMP-activated Protein Kinase (AMPK) Activation and IKK/NF-{kappa}B/PTEN Suppression J. Biol. Chem., September 5, 2008; 283(36): 24889 - 24898. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Zhao, E. Lee, A. M. Zukas, M. K. Middleton, M. Kinder, P. S. Acharya, J. A. Hall, D. J. Rader, and E. Pure CD44 Expressed on Both Bone Marrow-Derived and Non-Bone Marrow-Derived Cells Promotes Atherogenesis in ApoE-Deficient Mice Arterioscler Thromb Vasc Biol, July 1, 2008; 28(7): 1283 - 1289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Croons, W. Martinet, A. G. Herman, and G. R. Y. De Meyer Differential Effect of the Protein Synthesis Inhibitors Puromycin and Cycloheximide on Vascular Smooth Muscle Cell Viability J. Pharmacol. Exp. Ther., June 1, 2008; 325(3): 824 - 832. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Debing, E. Peeters, C. Demanet, M. De Waele, and P. Van den Brande Markers of Inflammation in Patients With Symptomatic and Asymptomatic Carotid Artery Stenosis: A Case-Control Study Vascular and Endovascular Surgery, May 1, 2008; 42(2): 122 - 127. [Abstract] [PDF]
|
|
|
|
|
|
A. Malarstig, S. Sigurdsson, P. Eriksson, G. Paulsson-Berne, U. Hedin, L. Wallentin, A. Siegbahn, A. Hamsten, and A.-C. Syvanen Variants of the Interferon Regulatory Factor 5 Gene Regulate Expression of IRF5 mRNA in Atherosclerotic Tissue But Are Not Associated With Myocardial Infarction Arterioscler Thromb Vasc Biol, May 1, 2008; 28(5): 975 - 982. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. R. Mohler III, C. M. Ballantyne, M. H. Davidson, M. Hanefeld, L. M. Ruilope, J. L. Johnson, A. Zalewski, and for the Darapladib Investigators The Effect of Darapladib on Plasma Lipoprotein-Associated Phospholipase A2 Activity and Cardiovascular Biomarkers in Patients With Stable Coronary Heart Disease or Coronary Heart Disease Risk Equivalent: The Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Study J. Am. Coll. Cardiol., April 29, 2008; 51(17): 1632 - 1641. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Petrovan, Y. Yuan, and L. K. Curtiss Expression of the Lystbeige mutation is atheroprotective in chow-fed apolipoprotein E-deficient mice J. Lipid Res., February 1, 2008; 49(2): 429 - 437. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Schneider, Y. Zhu, T. Coleman, and C. F. Semenkovich Macrophage 3 Integrin Suppresses Hyperlipidemia-Induced Inflammation by Modulating TNF{alpha} Expression Arterioscler Thromb Vasc Biol, December 1, 2007; 27(12): 2699 - 2706. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. Becker Emerging Paradigms, Platforms, and Unifying Themes in Biomarker Science J. Am. Coll. Cardiol., October 30, 2007; 50(18): 1777 - 1780. [Full Text] [PDF]
|
|
|
|
|
|
P. K. Cheruvu, A. V. Finn, C. Gardner, J. Caplan, J. Goldstein, G. W. Stone, R. Virmani, and J. E. Muller Frequency and Distribution of Thin-Cap Fibroatheroma and Ruptured Plaques in Human Coronary Arteries: A Pathologic Study J. Am. Coll. Cardiol., September 4, 2007; 50(10): 940 - 949. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Koenig Cardiovascular Biomarkers: Added Value With an Integrated Approach? Circulation, July 3, 2007; 116(1): 3 - 5. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Matfin Review: Biomarkers in clinical trials and drug development: measurement of cardiometabolic risk The British Journal of Diabetes & Vascular Disease, May 1, 2007; 7(3): 101 - 106. [Abstract] [PDF]
|
|
|
|
|
|
W. Koenig Serum Amyloid P Component and Cardiovascular Disease: Is There a Sensible Link? Arterioscler Thromb Vasc Biol, April 1, 2007; 27(4): 698 - 700. [Full Text] [PDF]
|
|